Key result
Statin use is linked to ~24% lower ASCVD risk in adults aged 75-84 with T2D.
Why the study?
Does statin treatment reduce atherosclerotic CVD and mortality in adults aged 75 years or older with and without type 2 diabetes?
Cohort (n=46,864)
No
Does statin treatment reduce atherosclerotic CVD and mortality in adults aged 75 years or older with and without type 2 diabetes?
Effect estimate: HR 0.76 (95% CI 0.65 to 0.89)
Statins for primary prevention in adults ≥75 years old do not reduce ASCVD or mortality in those without diabetes, but provide significant protective benefits in those with type 2 diabetes up to age 85.
No takes yet. Share an insight, caveat, or question.
Statin use may be considered for primary prevention in adults 75-84 with diabetes; leaves open confirmation by randomized trials.
Ramos et al. (2018) conducted a cohort in atherosclerotic cardiovascular disease (n=46,864). statins vs. placebo was evaluated on atherosclerotic CVD and all cause mortality (HR 0.76, 95% CI 0.65 to 0.89). Statin treatment significantly reduced the incidence of atherosclerotic CVD by 24% and all cause mortality by 16% in participants aged 75-84 years with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: